Stockreport

Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]

Theriva Biologics, Inc.  (TOVX) 
PDF review of early stage SYN-004 trial in transplant recipients to prevent graft-versus-host disease. Adverse events ((AEs)) and serious adverse events ((SAEs)) observed [Read more]